Cancer immunotherapy is becoming a standard of care. Are you incorporating it into your practice and keeping current on its rapidly increasing applications?
To learn how to effectively incorporate immunotherapy into your practice, register to attend this program at a location near you.
Start your learning today! Register for the free Advances in Cancer Immunotherapy™ 2017 Video Series online class on SITC Cancer Immunotherapy connectED.
ACI Registration Costs
Continuing Education Info
ACI Online Programs
Specifically designed by the Society for Immunotherapy of Cancer (SITC), the Advances in Cancer Immunotherapy™ (ACI) programs are introductory, CME-, CNE- and CPE-certified programs, presented by leading, local authorities in tumor immunology and cancer immunotherapy.
These six-hour programs will facilitate understanding of the clinical applications of immunotherapy for disease states with FDA-approved treatments; strategies for overcoming operational and reimbursement barriers to implementing immunotherapy in a community setting; and the identification and management of immune-related adverse events.
Attendees will also have an opportunity for connecting with regional experts in the immunotherapy field at the in-person event, through two post-program webinars, and indefinitely through a dedicated online SITC CONNECT community forum.
New this year, SITC is partnering with the American Academy of Emergency Medicine (AAEM) and the Association of Community Cancer Centers (ACCC) to provide guidance for emergency physicians in identifying and managing patients who present to the ER with immune-related adverse events, and practical information about the necessary hospital operations for providing immunotherapy and strategies for obtaining reimbursement.
The target audience for ACI program series is patient care providers and others who wish to learn the basic principles of tumor immunology and immunotherapy, and to improve their ability to integrate immunotherapy into state-of-the-art clinical management for their patients. This intended audience includes clinical oncologists, registered nurses, nurse practitioners, pharmacists, emergency physicians, allied health professionals, other patient care providers, students and patient advocates.
The topics that will be covered during each program in the series are as follows:
ACI program attendees receive access to enduring materials as soon as they are available. Enduring materials are also made available to the public according to a specific timeline.
Click here to learn more about accessing the enduring materials.
The 2017 ACI series is brought to you in collaboration with the American Academy of Emergency Medicine and Association of Community Cancer Centers.
Event staff will be glad to assist you with any special needs (i.e., physical, dietary, etc.). Please contact SITC prior to the event at (414) 271-2456.
Asim Amin, MD, PhD Levine Cancer Institute, Carolinas Medical Center
Joseph W. Fay, MD Fay Foundation
Keith L. Knutson, PhD Mayo Clinic, Jacksonville Campus
Hideho Okada, MD, PhD University of California, San Francisco
Laura S. Wood, RN, MSN, OCN Cleveland Clinic Taussig Cancer Center
Therapy-related myeloid neoplasms (WHO classification) with mutated TP53 or complex chromosome aberrations are not likely to be cured with targeted agents. These neoplasms comprise a group of clonal hematopoietic stem cell disorders related to prior ...
The Department of Immunology, Genetics and Pathology (IGP) at Uppsala University in Sweden is involved in an ongoing effort to collect cancer patient data in an initiative entitled U-CAN. By June of this year, the biobank has grown to approximately ...
It is the recent modest single agent activity of programmed death-ligand 1 and programmed death receptor-1 antibodies for those with breast cancer that is generating hope for use of immunotherapy in breast cancer. To ponder in the meantime, in preparation ...
Tel: +1 414 271 2456 | Fax: +1 414 276 3349 | Email: email@example.com